Equities Analysts Set Expectations for HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for Harmony Biosciences in a research note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will earn $2.43 per share for the year, down from their previous estimate of $3.27. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Other equities research analysts also recently issued research reports about the stock. Needham & Company LLC reissued a “buy” rating and set a $50.00 price objective on shares of Harmony Biosciences in a research report on Tuesday, February 25th. HC Wainwright lowered their price objective on shares of Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday. Mizuho lowered their price objective on shares of Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating for the company in a research report on Thursday, February 20th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research report on Tuesday, February 11th. They set a “buy” rating and a $55.00 price objective for the company. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $53.11.

Harmony Biosciences Stock Up 3.4 %

Shares of HRMY stock opened at $33.85 on Friday. The firm has a fifty day moving average of $36.63 and a 200-day moving average of $35.79. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. Harmony Biosciences has a 12-month low of $28.14 and a 12-month high of $41.61. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of 16.04, a P/E/G ratio of 0.47 and a beta of 0.80.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $201.30 million during the quarter, compared to the consensus estimate of $201.25 million. During the same quarter in the prior year, the firm earned $0.45 earnings per share. The business’s quarterly revenue was up 19.5% on a year-over-year basis.

Insider Buying and Selling at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 1,123 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total value of $44,920.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Sandip Kapadia sold 25,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total transaction of $1,004,500.00. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock worth $2,831,679 over the last quarter. 30.80% of the stock is currently owned by insiders.

Institutional Trading of Harmony Biosciences

A number of large investors have recently added to or reduced their stakes in HRMY. GAMMA Investing LLC lifted its stake in shares of Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after buying an additional 436 shares during the last quarter. Mendota Financial Group LLC lifted its stake in shares of Harmony Biosciences by 24,125.0% during the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after buying an additional 965 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Harmony Biosciences during the 4th quarter worth about $41,000. KBC Group NV lifted its stake in shares of Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Harmony Biosciences during the 3rd quarter worth about $74,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.